IOncology

China, Japan, and South Korea have long ranked among the countries with the highest incidence of lung cancer worldwide. With a heavy disease burden, urgent unmet medical needs, and remarkably similar disease characteristics, strengthening trilateral collaboration among these East Asian nations is critical to advancing clinical oncology and addressing shared challenges in lung cancer management.

Editor’s Note The European Society for Medical Oncology (ESMO) 2025 Annual Congress, held in Berlin, Germany from October 17–21, gathered leading global experts to share groundbreaking advances in cancer diagnosis…

Editor’s Note: At the 2025 ESMO Annual Congress in Berlin, multiple innovative therapies attracted wide attention. Among them, the selective PI3K-α inhibitor JS105 released the first results from two Phase…

In the second-line treatment of hormone receptor–positive, HER2-negative (HR+/HER2–) advanced breast cancer, CDK4/6 inhibitors combined with fulvestrant have become the standard of care. However, variations in efficacy and safety profiles among different inhibitors remain an important clinical consideration.

The 2025 European Society for Medical Oncology (ESMO) Annual Congress, held in Berlin, Germany from October 17 to 21, brought together global experts to present cutting-edge advances in cancer research — from basic science to translational breakthroughs and clinical innovation.

The PATINA (AFT-38) trial is a randomized, open-label, phase III study designed to evaluate the efficacy and safety of palbociclib + HER2-targeted therapy + endocrine therapy versus HER2-targeted therapy + endocrine therapy alone in patients with HR+/HER2+ metastatic breast cancer following induction therapy. Previous data from PATINA demonstrated that the addition of palbociclib significantly prolonged median progression-free survival (mPFS) in this patient population.

At the 2025 ESMO Annual Congress, the long-term follow-up results of the GeparNuevo trial (Abstract #292MO) were presented. The data showed that although durvalumab combined with neoadjuvant chemotherapy did not significantly improve the pathological complete response (pCR) rate, it significantly prolonged survival outcomes, including invasive disease-free survival (iDFS), distant disease-free survival (DDFS), and overall survival (OS). Notably, among patients who achieved pCR, the 7-year OS rate reached 100% in the durvalumab group, suggesting that immunotherapy may provide long-term benefits through sustained immune surveillance. Oncology Frontier invited Professor Zhang Juliang from Xijing Hospital, Air Force Medical University, to comment on these findings and discuss strategies for optimizing immunotherapy in early triple-negative breast cancer (TNBC).

At the 2025 ESMO Annual Congress, the overall survival (OS) data from the monarchE trial were released, showing that abemaciclib combined with endocrine therapy significantly improved survival in patients with HR+/HER2- high-risk early breast cancer, reducing the risk of death by 15.8%.